Journal Pre-proof

Towards understanding the effective use of antibiotics for sepsis

M. Schinkel, MD, K. Paranjape, Msc, J. Kundert, Msc, R.S. Nannan Panday, PhD, N. Alam, PhD, P.W.B. Nanayakkara, FRCP

PII: S0012-3692(21)00763-7

DOI: https://doi.org/10.1016/j.chest.2021.04.038

Reference: CHEST 4224

To appear in: CHEST

Received Date: 8 July 2020

Revised Date: 9 March 2021

Accepted Date: 18 April 2021

Please cite this article as: Schinkel M, Paranjape K, Kundert J, Panday RSN, Alam N, Nanayakkara PWB, Towards understanding the effective use of antibiotics for sepsis, *CHEST* (2021), doi: https://doi.org/10.1016/j.chest.2021.04.038.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Copyright © 2021 Published by Elsevier Inc under license from the American College of Chest Physicians.



Title

Towards understanding the effective use of antibiotics for sepsis.

Running title

Effective use of antibiotics for sepsis.

Authors

M. Schinkel, MD^{1, 2*}

K. Paranjape, Msc^{1, 3}*

J. Kundert, Msc³

R.S. Nannan Panday, PhD^{1,4}

N. Alam, PhD¹

P.W.B. Nanayakkara, FRCP¹

 ¹ Section General and Acute Internal Medicine, Department of Internal Medicine, Amsterdam Public Health Research Institute, Amsterdam UMC, location VU University Medical Center. De Boelelaan 1118, 1081HZ, Amsterdam, The Netherlands.
² Center of Experimental and Molecular Medicine (C.E.M.M.), Amsterdam UMC, location Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.
³Roche Diagnostics Corporation, 9115 Hague Road, Indianapolis, IN 46256, United States.
⁴Center for Population Health Sciences, Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore.

*Both authors contributed equally to the manuscript.

Word count

3199

Corresponding author

Prof. P.W.B. Nanayakkara, MD, PhD, FRCP

Head, Section General and Acute Medicine

Department of Internal Medicine

Amsterdam UMC , Location VU University Medical Center

De Boelelaan 1118

1081 HZ, Amsterdam

The Netherlands

p.nanayakkara@amsterdamumc.nl

Tel: +3120444444 ext. 6791

Financial support

No financial support was received for this work.

Conflict of interest

The authors declare no conflict of interest.

Abstract

Background

The benefits of early antibiotics for sepsis have recently been questioned. Evidence for this mainly comes from observational studies. The only randomized trial on this subject, the PHANTASi trial, did not find significant mortality benefits from early antibiotics. It is still plausible that subgroups of patients benefit from this practice, given the heterogeneous nature of sepsis.

Research Question

Do subgroups of sepsis patients experience 28-day mortality benefits from early administration of antibiotics in a prehospital setting? And what key traits drive these benefits?

Study Design and Methods

We used machine learning to conduct exploratory partitioning cluster analysis to identify possible subgroups of sepsis patients who may benefit from early antibiotics. We further tested the influence of several traits within these subgroups using a logistic regression model.

Results

We found a significant interaction between age and benefits of early antibiotics (p=0.03). When we adjusted for this interaction and several other confounders, there was a significant benefit of early antibiotic treatment (OR = 0.07; 95%-Cl = 0.01-0.79; p = 0.03).

Interpretation

An interaction between age and benefits of early antibiotics for sepsis has not been reported before. When validated, it can have major implications for clinical practice. This new insight into benefits of early antibiotic treatment for younger sepsis patients may enable more effective care.

Keywords

Antibiotics; Sepsis; Age; Machine Learning; PHANTASi trial; Mortality; Prehospital

proprod

Sepsis is a major health problem worldwide. A recent study estimated the global incidence of sepsis to be nearly 50 million cases annually with 11 million sepsis-related deaths¹. Dysregulation of the host response to infections can cause organ dysfunction and subsequently leads to these high mortality rates². Sepsis is a truly heterogeneous syndrome^{3,4}, caused by different pathogens at various sites (e.g. respiratory tract, urinary tract, or abdominal), which makes it difficult to develop general guidelines that will benefit all sepsis patients.

Researchers have aimed to identify specific subgroups of sepsis patients in order to tailor the treatment. Seymour and colleagues, for example, categorized four clinical sepsis phenotypes with similar traits, that may also respond similarly to certain treatments⁵. Current sepsis treatment mainly includes administration of antibiotics and intravenous fluids. The subcategorization of sepsis patients could help use these options more effectively when given to the right patient at the right time.

Most patients suspected of having systemic infections rapidly receive antibiotic treatment in the emergency department (ED). There is a long-standing belief that every hour of delay in administration of antibiotics leads to an increased risk of mortality, as suggested by Kumar et al. in 2006⁶. Many treatment protocols for sepsis have been guided by this belief, ultimately resulting in an international effort called the Surviving Sepsis Campaign (SSC) guideline 1-hour bundle⁷.

Journal Pre-proof

Recently the benefits of early antibiotic treatment in all patients with suspected sepsis have been questioned^{8–11}. Physicians are forced to sacrifice diagnostic accuracy, in order to treat these patients early, which contributes to overuse of antibiotics^{8,12,13}. A Dutch study reported that 29% of suspected sepsis patients in the ED were unlikely to even have an infection¹². In a recent review, we evaluated the literature on the benefits of early antibiotics for sepsis and concluded that the evidence for this is mainly derived from observational studies⁸. The only randomized controlled trial on this subject, called the Prehospital Antibiotics Against Sepsis (PHANTASi) trial, conducted by our research group, did not show significant benefits of early antibiotic treatment in a pre-hospital setting¹⁴.

Although there is no conclusive evidence supporting the early use of antibiotics in all patients with suspected sepsis, it is plausible that subgroups of patients may benefit from early antibiotic treatment. In this study, we aim to identify subgroups of patients in the PHANTASi trial cohort who are likely to benefit from early antibiotic treatment and study their key traits using machine learning¹⁵.

Study Design and Methods

Database

The PHANTASi trial database was used for this study¹⁴. The PHANTASi trial randomized 2672 patients with suspected sepsis to either receive antibiotic treatment in the ambulance (intervention) or antibiotic treatment once the patient had arrived in the ED (control). This resulted in a median difference in time to antibiotics of 96 minutes (IQR: 36-128) between the groups. The study ran between June 2014 and June 2016. Patients were included when they were at least 18 years of age, were suspected of having an infection, and had at least two Systemic Inflammatory Response Syndrome (SIRS) criteria, with a mandatory temperature \geq 38°C or \leq 36°C. The original trial was registered at ClinicalTrials.gov, number NCT01988428. More details on this study can be found here^{14,16}.

Vital parameters and laboratory results were recorded in the ambulance and in the ED. Any treatments, including an early dose of antibiotics in the ambulance in the intervention group, were recorded. Diagnoses were confirmed by an expert panel and sepsis severity was categorized according to the 2001 international sepsis criteria¹⁷, which were the gold standard at the time. The study was powered to detect differences in the primary outcome, which was 28-day mortality¹⁴.

Statistical Analysis

Statistical analyses were performed in R 3.5¹⁸, and in R modules within the Alteryx software (Alteryx Inc, Irvine CA, USA)¹⁹, which is an extraction transformation and loading application. Differences between non-normally distributed and continuous variables were assessed with

Journal Pre-proof

a Mann-Whitney U test²⁰. Differences between categorical variables were tested with a chisquare test. Normality of the data was assessed with histograms and Q-Q plots. A two-tailed p-value of <0.05 was considered to be statistically significant.

Machine learning algorithms were used to conduct exploratory partitioning cluster analysis to identify possible factors impacting the benefits of early antibiotic treatment. This clustering approach involved three broad phases: exploratory data analysis, preliminary cluster diagnostics, and then focused cluster partitioning based on key traits.

During the exploratory data analysis, unsupervised machine learning techniques (K-means, K-medians, and Neural Gas clustering) were performed in order to identify any relevant cluster patterns exhibited by combinations of traits with either known or suspected associations with 28-day mortality. Twenty-two exploratory analyses were performed involving various traits (outlined in e-Table 1: Exploratory K-Centroids Diagnostic Data Mining Trials). These clusters assessed various clinical factors obtained in the ambulance, ED, as well as deterioration between ambulance and ED (delta in particular traits such as heart rate, respiratory rate, etc.). We visually assessed each cluster pattern outcome to gain general insight and help shape the direction of subsequent, more focused, clustering techniques.

We identified three specific focused clustering combinations, outlined in Table 1, for further evaluation and subsequent cluster diagnostics, based specifically on clinical factors obtained in the ambulance. A thorough pre-assessment K-Centroid diagnostic analysis was performed for these specific combinations of key traits. This involved identifying possible traits that

8

Journal Pre-proof

could have a strong cluster relationship, and then algorithmically evaluating the mathematically ideal number of clusters (k) for each combination. Cluster diagnostic results, including supporting Adjusted Rand (ARI) and Calinski-Harabasz (CH) indices for each selected k-value, are represented in Table 1. The ARI was used to help provide a measure of agreement, or similarity, between partitions; the CH provided a measure for separation and inter-cluster density. The assessment process evaluated the suitable number of clusters (k) by maximizing ARI and CH, when compared to k alternatives, in order to increase cluster performance and quality. Once the number of clusters was determined for each possible trait combination, the clustering assignment was attempted and associated to each patient record. We used K-Means clustering for each grouping and no additional unit standardization was applied to input fields. See Table 1 for further details. These cluster analyses focused primarily on better understanding previously unknown relationships within the data, as well as to help focus the direction of subsequent, more traditional, multivariable logistic regression statistical analysis.

To further test associations between 28-day mortality and various traits, a multivariable logistic regression model was used. The raw model was adjusted for confounders using the 10% change-in-estimate criterion, as is one of the accepted methods of confounder identification^{21,22}. Also, full models with all a priori identified theoretical confounders are presented²³.

In some cases, age was not used as a continuous variable, but as a dichotomous variable, The categories were created by splitting the dataset in the 50% youngest and 50% oldest

9

patients, in order to obtain equally large numbers of patients in both groups²². The age ranges in these groups were 18 - 75 and 76 - 100 years respectively.

ournal Prevension

Results

Exploratory partitioning cluster analysis

Clusters of similar patients were created based on various patient characteristics and with the use of various unsupervised machine Learning techniques. Based on the most favorable Rand index values, a K-means cluster algorithm based on age, heart rate in the ambulance, and temperature in the ambulance was selected to generate two clusters (mean ARI: 0.93; mean CH: 4485.1). The patterns produced using this model consistently resulted in strong ties associated with the age trait, seen in figure 1, with partitioning occurring around the age of 70. Figure 1 illustrates three different two-dimensional representations of the same clusters, generated based on age, heart rate, and temperature. Though these are simplified representations of the three-dimensional clusters, they clearly show that the age trait is the most important driver of the clusters.

In figure 2a, patients were categorized based on designated cluster and separated by randomization group and 28-day mortality outcome. For simplicity, we opted to only present a two-dimensional representation in this figure, since further insights are mostly derived from the age axis. The figure identifies the control group (antibiotics administered in the ED) from the intervention group (antibiotics in the ambulance), and separates patients who survived after 28 days from those deceased. Cluster 1 (denoted: O) resulted in 1671 patients with a mean age of 80.6. Cluster 2 (denoted: X) produced 848 patients with a mean age of 57.5. There were also 153 patients categorized as outliers based on inconclusive clinical factors and were not assigned a cluster. Additional analysis yields that younger patients seen in cluster 2 may exhibit a slight lowering of the overall 28-day mortality rate in the

Journal Pre-proof

intervention group (4.0%) when compared to younger patients in the control group (5.0%), while this is less pronounced in cluster 1 with older patients. Mortality rate percentages associated with each cluster are further outlined in figure 2b.

Logistic regression modelling

We created an association model to quantify the initial finding of a possible interaction between age and the effect of early antibiotic treatment. We used a logistic regression model to explain 28-day mortality in all patients who were categorized as having sepsis (n=2617). This number differs from the complete population (n=2672), because some patients had diagnoses other than sepsis in retrospect. Baseline characteristics of the included patients are presented in Table 2.

We used 28-day mortality as dependent variable and intervention with early antibiotics (yes/no) as the main independent variable in our model. We also added the interaction between intervention and age (as a continuous variable) in the raw model, since this was the effect modifier we aimed to study. In the raw model, the effect of the intervention on 28-day mortality (OR = 0.13; 95%-CI = 0.02-1.10; p = 0.061) as well as the interaction term between age and the benefit of the intervention (OR = 1.03; 95%-CI = 1.00-1.05; p = 0.066) did not meet traditional measures of clinical significance. We then adjusted the model for a priori selected potential confounders, based on the 10% change-in-estimate criterion. This resulted in an adjustment based on qSOFA score and Charlson comorbidity index, after which other variables did not meaningfully change this adjusted model. The adjusted model showed a significant benefit of the intervention on 28-day mortality (OR = 0.07; 95%-CI = 0.01-0.79; p = 0.03) as well as a significant interaction term between age and the benefit of the intervention on 28-day mortality (OR = 0.07; 95%-CI = 0.01-0.79; p = 0.03) as well as a significant interaction term between age and the benefit of

the intervention (OR = 1.03; 95%-CI = 1.00-1.06; p = 0.03). Additionally, we created a full model based on all a priori selected potential confounders, irrespective of their influence in this dataset. This approach has been proposed in the literature and provided similar results as the adjusted model, as can be seen in Table 3, which also shows the full list of variables that we had selected as possible confounders.

Age as a categorical value

In the initial model, we used age as a continuous variable. Since we cannot be sure that the beneficial effects of early antibiotics decrease linearly with increasing age, we also created a model based on age groups. The age groups were created by a split based on the median age. This resulted in a cut off at the age of 76. The raw model, with age as dichotomous variable, did not show significant benefits of the intervention (OR = 0.68; 95%-CI = 0.02-1.10; p = 0.126), or interaction term between age and the benefit of the intervention (OR = 1.65; 95%-CI = 0.90-3.05; p = 0.110). We then adjusted the model for the same variables as the adjusted model in the previous analysis, and noticed that differences in the benefits of early antibiotics (OR = 0.63 95%-Cl = 0.36-1.06; p = 0.082), just as the interaction term between age and the benefit of the intervention (OR = 1.89; 95%-Cl = 0.99-3.63; p = 0.055) did not meet traditional measures of clinical significance. The full model, adjusted a priori with identified possible confounders, showed a similar benefit of early antibiotics as with age as a continuous variable (OR = 0.59; 95%-CI = 0.34-1.05; p = 0.063) and the interaction term between age and the benefit of the intervention also presented similar results (OR = 2.17; 95%-CI = 1.11-4.30; p = 0.025). See Table 3 for further details.

Different cut-off values for age groups

In the analysis which used age as a dichotomous variable, we chose to split the groups based on the median age. Supplementary Table 2 presents results for other cut-off values. Many cut-off values between 75 and 83 years of age showed significant results.

Journal Pression

Discussion

We re-evaluated the PHANTASi trial cohort to identify subgroups of patients who may benefit from early antibiotic treatment and the traits driving these subgroups. We found a significant interaction between age and intervention with early antibiotics, associating early antibiotic treatment with a significant decrease in 28-day mortality among younger patients. We showed that there is a significant interaction between age and the effect of early antibiotic treatment on mortality (p=0.04). When we adjusted for this interaction, along with other potential confounders, there was a significant association between intervention with early antibiotics and 28-day mortality (OR = 0.07; 95%-CI = 0.007-0.75; p = 0.03).

In context

The three largest observational studies which evaluate the effect of time of antibiotic administration on mortality, have not assessed the interaction between the age of the patients and the benefits of early antibiotic treatment^{24–26}. Over the past year, our research group has received several inquiries about the non-significant, but notably low relative risk of mortality in the younger patients in the original PHANTASi trial, which spiked our interest in finding subgroups of patients who may have benefitted from early antibiotics. We opted to start this study by performing exploratory partitioning cluster analysis, rather than focusing specifically on age, since this allowed us to provide a broader view of potential patient factors that could be associated with benefits of early antibiotics treatment. However, we soon found that age seemed to be the most important driver of clusters and that we needed to focus on this trait.

Residual confounding

We tested the robustness of our results by using age as a continuous as well as a dichotomous variable, as well as using empirical and theoretical criteria to select the confounders we adjusted for. We thereby hoped to have limited residual confounding which is inherent to secondary analyses. Since this study is based on secondary analyses, p-values are difficult to interpret. The original study was not designed to detect this interaction, which makes it hard to find statistically significant results. We therefore focused on evaluating whether our findings remained similar when we examined different subgroups or adjusted the model for different potential confounders, while still providing p-values and confidence intervals for clarity.

We showed that the interaction between age and the intervention with early antibiotics was independent of the cut-off value we used for the age groups. In supplementary Table 2, we report p-values for the interaction between age and intervention for cut-off levels between the age of 70 and 85, which are significant at multiple thresholds. The absence of significant results at the lower and higher ends of that range is likely a reflection of the low numbers of patients and events in one of the two groups in those situations. This can also explain why the relative risk in the original publication of the PHANTASi trial did not reach statistical significance. The cut-off in the original publication was 65, which is a commonly accepted cut-off to define younger and older patients, but created a younger group (n=600) that was considerably smaller than the elderly group (n=2017).

16

Clinical value

The interaction between age and benefits of early antibiotic treatment, which is associated with significant improvements in 28-day mortality in younger sepsis patients, can be clinically relevant. Knowing in which subcategory of patients benefits of early antibiotic treatment can be expected, will enable effective and optimized care.

Our results suggest that we should immediately consider antibiotic treatment in younger patients, while early treatment does not seem to have much beneficial effects in older sepsis patients. We do not propose a specific age cut-off for the benefits of early antibiotics, but we do believe that additional time to do a proper work-up may be taken with elderly sepsis patients, to confirm the diagnosis before initiating antibiotic treatment. This is especially helpful since diagnosing sepsis in the elderly is often more challenging due to non-specific presentations²⁷. Recent research indicates that early administration of antibiotics is associated with higher mortality when given to patients with greater diagnostic uncertainty²⁸. Arguably, the diagnostic uncertainty may be higher in elderly patients, given the non-specific presentations. This provides an additional argument for withholding antibiotic treatment until the diagnosis is clearer.

We should note that our study only included patients with symptoms of sepsis. It may well be that early administration of antibiotics for elderly sepsis patients in practice is even less desirable, since this practice may even harm the patients with less specific presentations. Furthermore, there was only a small decrease in time to antibiotics (96 minutes) by intervening with antibiotics in the ambulance in this trial. In many settings, administration of

17

antibiotics in the ambulance will result in larger decreases in time to antibiotics, which is possibly associated with an even stronger mortality benefit.

Strengths

We examined an interaction which to our knowledge has never been reported before. The interaction between age and benefits of early antibiotic treatment may explain part of the variance in benefits of early antibiotic treatment which is observed throughout the literature on this subject^{3,29}. Furthermore, we used data from the single randomized trial on this subject, which lowers the chance of residual. Lastly, we could evaluate the effect of potential confounders such as antibiotic sensitivities, while most studies on this subject lack this important data to evaluate adequacy of antibiotic treatments³⁰.

Limitations

We recognize the limitations of performing secondary analyses. Subgroup effects can be misleading and can be explained by chance³¹. To minimize the risk that we found these results by chance, we performed several different analyses to see whether our results were robust. A second limitation is that we were not able to validate our findings in a similar cohort, since the PHANTASi trial was the only randomized trial on this subject and was conducted in a very specific setting. Validation of our findings in existing large observational cohorts could provide additional strength to our findings. However, such cohorts carry high risk of residual confounding and will not be able to undeniably validate or disprove our findings. A definite answer to whether young patients benefit from early antibiotics can only be given by another randomized study such as the PHANTASi trial.

Interpretation

In conclusion, we have re-examined the effects of early antibiotic treatment for sepsis, finding a significant interaction between age and mortality benefits of this practice. Young sepsis patients seem to experience a significant mortality benefit from early antibiotic treatment in the ambulance, which reduces as age increases. This interaction has not been reported before. Validation studies in other cohorts are needed to confirm our findings, which could lead to a shift in the way we think about the pathophysiology of sepsis and the most optimal treatment strategies.

Acknowledgments

MS, KP, RSNP, NA and PWBN conceived the study. NA and RSNP were responsible for the database and PWBN was responsible for study supervision. MS, KP, JK and PWBN analyzed and interpreted that data. MS, KP, JK, RSNP and PWBN drafted the manuscript. All authors read, revised, and approved the final manuscript.

Declaration of interests

The authors declare no competing interests.

Financial support

No financial support was received for this work.

Take Home Point:

Study question Are there specific subgroups of sepsis patients who are more likely to benefit from early antibiotic treatment?

Results

We found a significant interaction between age and benefits of early antibiotics, associating early treatment with a significant decrease in 28-day mortality among younger sepsis patients.

Interpretation

Our results suggest that we should immediately consider antibiotic treatment in younger patients, while early treatment does not seem to have much beneficial effects in older sepsis patients.

Journal Prevention

References

- Rudd KE, Johnson SC, Agesa KM, et al. Global, regional, and national sepsis incidence and mortality, 1990–2017: analysis for the Global Burden of Disease Study. *Lancet*. 2020;395(10219):200-211. doi:10.1016/S0140-6736(19)32989-7
- 2. Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315(8):801. doi:10.1001/jama.2016.0287
- de Grooth HJ, Postema J, Loer SA, Parienti JJ, Oudemans-van Straaten HM, Girbes AR. Unexplained mortality differences between septic shock trials: a systematic analysis of population characteristics and control-group mortality rates. *Intensive Care Med*. 2018;44(3):311-322. doi:10.1007/s00134-018-5134-8
- 4. Schinkel M, Virk HS, Nanayakkara PWB, van der Poll T, Wiersinga WJ. What Sepsis Researchers Can Learn from COVID-19. *Am J Respir Crit Care Med*. 2021;203(1):125-127. doi:10.1164/rccm.202010-4023LE
- 5. Seymour CW, Kennedy JN, Wang S, et al. Derivation, Validation, and Potential Treatment Implications of Novel Clinical Phenotypes for Sepsis. *JAMA*. 2019;321(20):2003. doi:10.1001/jama.2019.5791
- 6. Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock*. *Crit Care Med*. 2006;34(6):1589-1596. doi:10.1097/01.CCM.0000217961.75225.E9
- Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. *Intensive Care Med*. 2017;43:304-377. doi:10.1007/s00134-017-4683-6
- 8. Schinkel M, Nannan Panday RS, Wiersinga WJ, Nanayakkara PWB. Timeliness of antibiotics for patients with sepsis and septic shock. *J Thorac Dis Publ Ahead Print*. Published online 2019. http://jtd.amegroups.com/article/view/32687
- 9. Gilbert DN, Kalil AC, Klompas M, Masur H, Winslow DL. IDSA POSITION STATEMENT: Why IDSA Did Not Endorse the Surviving Sepsis Campaign Guidelines. *Clin Infect Dis*. 2017;45:486. doi:10.1093/cid/cix997
- Spiegel R, Farkas JD, Rola P, et al. The 2018 Surviving Sepsis Campaign's Treatment Bundle: When Guidelines Outpace the Evidence Supporting Their Use. *Ann Emerg Med*. 2019;73(4):356-358. doi:10.1016/j.annemergmed.2018.06.046
- 11. Rothrock SG, Cassidy DD, Barneck M, et al. Outcome of Immediate Versus Early Antibiotics in Severe Sepsis and Septic Shock: A Systematic Review and Meta-analysis. *Ann Emerg Med*. 2020;0(0). doi:10.1016/j.annemergmed.2020.04.042
- Minderhoud TC, Spruyt C, Huisman S, Oskam E, Schuit SCE, Levin MD. Microbiological outcomes and antibiotic overuse in Emergency Department patients with suspected sepsis. *Neth J Med*. 2017;75(5):196-203. Accessed September 12, 2019. http://www.ncbi.nlm.nih.gov/pubmed/28653945
- Klein Klouwenberg PMC, Cremer OL, van Vught LA, et al. Likelihood of infection in patients with presumed sepsis at the time of intensive care unit admission: A cohort study. *Crit Care*. 2015;19(1). doi:10.1186/s13054-015-1035-1
- 14. Alam N, Oskam E, Stassen PM, et al. Prehospital antibiotics in the ambulance for sepsis: a multicentre, open label, randomised trial. *Lancet Respir Med*. 2018;6(1):40-50.

doi:10.1016/S2213-2600(17)30469-1

- 15. Schinkel M, Paranjape K, Panday RSN, Skyttberg N, Nanayakkara PWB. Clinical applications of artificial intelligence in sepsis: A narrative review. *Comput Biol Med*. Published online October 2019:103488. doi:10.1016/j.compbiomed.2019.103488
- 16. Alam N, Van De Ven PM, Oskam E, et al. Study protocol for a Multi-centre, Investigatorinitiated, randomized controlled trial to compare the effects of prehospital antibiotic treatment for sepsis patients with usual care after training Emergency Medical Services (EMS) Personnel in Early Recognition (- the Prehospital ANTibiotics Against Sepsis (PHANTASi) trial. *Acute Med*. 2016;15(4):176-184.
- 17. Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. *Crit Care Med*. 2003;31(4):1250-1256. doi:10.1097/01.CCM.0000050454.01978.3B
- 18. R: The R Project for Statistical Computing. Accessed May 25, 2020. https://www.r-project.org/
- 19. Self-Service Data Analytics Platform | Alteryx. Accessed June 11, 2020. https://www.alteryx.com/
- 20. Olsen CH. Review of the Use of Statistics in Infection and Immunity. *Infect Immun*. 2003;71(12):6689-6692. doi:10.1128/IAI.71.12.6689-6692.2003
- 21. Lee PH. Is a cutoff of 10% appropriate for the change-in-estimate criterion of confounder identification? *J Epidemiol*. 2014;24(2):161-167. doi:10.2188/jea.JE20130062
- 22. Twisk JWR. Inleiding in de toegepaste biostatistiek. Vol Vierde (on. Bohn Stafleu van Loghum; 2016. https://search.ebscohost.com/login.aspx?direct=true&db=nlebk&AN=1638989&site=ehost-live
- 23. Lee PH. Should we adjust for a confounder if empirical and theoretical criteria yield contradictory results? A simulation study. *Sci Rep.* 2014;4(1):1-14. doi:10.1038/srep06085
- 24. Ferrer R, Martin-Loeches I, Phillips G, et al. Empiric antibiotic treatment reduces mortality in severe sepsis and septic shock from the first hour: results from a guideline-based performance improvement program. *Crit Care Med*. 2014;42(8):1749-1755. doi:10.1097/CCM.0000000000330
- 25. Liu VX, Fielding-Singh V, Greene JD, et al. The Timing of Early Antibiotics and Hospital Mortality in Sepsis. *Am J Respir Crit Care Med*. 2017;196(7):856-863. doi:10.1164/rccm.201609-1848OC
- 26. Seymour CW, Gesten F, Prescott HC, et al. Time to Treatment and Mortality during Mandated Emergency Care for Sepsis. *N Engl J Med*. 2017;376(23):2235-2244. doi:10.1056/NEJMoa1703058
- 27. Juneja D. Severe sepsis and septic shock in the elderly: An overview. *World J Crit Care Med*. 2012;1(1):23. doi:10.5492/wjccm.v1.i1.23
- 28. Barbash I, Davis B, Seymour CW, Kahn JM. *D94 SEPSIS BIOLOGY AND HEALTH CARE DELIVERY / Mini Symposium Interaction Between Severity of Illness, Diagnostic Uncertainty and Antibiotic Timing in Patients with Suspected Infection*. Accessed September 10, 2020. www.atsjournals.org
- 29. Sterling SA, Miller WR, Pryor J, Puskarich MA, Jones AE. The Impact of Timing of Antibiotics on Outcomes in Severe Sepsis and Septic Shock: A Systematic Review and Meta-Analysis. *Crit*

Care Med. 2015;43(9):1907-1915. doi:10.1097/CCM.00000000001142

- 30. Singer M. Antibiotics for sepsis: Does each hour really count, or is it incestuous amplification? *Am J Respir Crit Care Med*. 2017;196(7):800-802. doi:10.1164/rccm.201703-0621ED
- 31. Sun X, Ioannidis JPA, Agoritsas T, Alba AC, Guyatt G. How to use a subgroup analysis users' guides to the medical literature. *JAMA J Am Med Assoc*. 2014;311(4):405-411. doi:10.1001/jama.2013.285063

boutinal pre-proof

Table 1. K-Centroids Cluster Diagnostics

K- Centroids	Min/Max	Number of	Troite	Number of	Diag Res	nostic sults		Cluster Results						
Method	Cluster Parameter	Traits Evaluated	Assessed	for Partitioning	Adjusted Rand (Mean)	Calinski- Harabasz (Mean)	Cluster	Size	Average Distance	Max Distance	Separation			
			Heart Rate (Ambulance); Systolic BP	3			1	1290	99.28	2691.1	34.4			
K-means			(Ambulance); Diastolic BP (Ambulance);				2	54	135.46	2694.8	982.3			
	2/8	6	Respiratory Rate (Ambulance); Temperature		0.61	342.11	3	1175	53 94	33.3				
			(Ambulance); Blood Oxygen Saturation (Ambulance)					1175	55.74	1010				
	2/8			5			1	734	5.92	13.5	8.87			
			Heart Rate (Ambulance);				2	2 865 3.34 8	8.02	7.66				
K-means		2	Temperature		0.80	5266.8	3	182	6.88	31.27	11.33			
			(Ambulance)				4	130	10.31	58.13	14.49			
							5	608	4.2	10.84	8.12			
			Age; Heart Rate				1	16/1	5.29	19.34	12.43			
K-means	2/8	3	(Ambulance); Temperature (Ambulance)	2	0.93	4485.1	2	848	8.59	39.58	11.66			
					20									

Table 2. Baseline characteristics of the complete sepsis population.

	Control (N=1113)	Intervention (N=1504)	Total (N=2617)	p value
Age, years				0.509
Median (IQR)	75.0 (65.0 <i>,</i> 83.0)	76.0 (66.0, 83.0)	76.0 (65.0 <i>,</i> 83.0)	
Sex				0.763
Male	638 (57%)	871 (58%)	1509 (58%)	
Female	475 (43%)	633 (42%)	1108 (42%)	
Youngest or oldest half of the patients				0.536
Under 76 years	559 (50%)	737 (49%)	1296 (50%)	
76 years or above	554 (50%)	767 (51%)	1321 (50%)	
Sepsis severity				0.341
Non-severe Sepsis	424 (38%)	576 (38%)	1000 (38%)	
Severe Sepsis	653 (59%)	863 (57%)	1516 (58%)	
Septic shock	36 (3%)	65 (4%)	101 (4%)	
Charslon Comorbidity Index		D [*]		0.988
Median (IQR)	1.0 (1.0, 3.0)	1.0 (0.0, 3.0)	1.0 (1.0, 3.0)	
Do not resuscitate order				0.307
No	666 (61%)	862 (59%)	1528 (60%)	
Yes	425 (39%)	598 (41%)	1023 (40%)	
quick Sequential Organ Failure Assessment Score (qSOFA)				0.003
2 or more	176 (17%)	310 (22%)	486 (20%)	
Smaller than 2	855 (83%)	1109 (78%)	1964 (80%)	
Use of immunosuppressiva medication				0.799
No	960 (86%)	1292 (86%)	2252 (86%)	
Yes	153 (14%)	212 (14%)	365 (14%)	
Patient already on oral antibiotics before randomisation				0.241
No	864 (79%)	1189 (81%)	2053 (80%)	
Yes	224 (21%)	274 (19%)	498 (20%)	
Pathogen resistant to ceftriaxone				0.015
Sensitive	1106 (100%)	1483 (99%)	2589 (100%)	
Resistant	0 (0%)	8 (1%)	8 (0%)	
Blood culture results from ambulance/emergency department				< 0.001
Negative	829 (75%)	1239 (83%)	2068 (80%)	
Positive	277 (25%)	252 (17%)	529 (20%)	
28-day mortality				0.753
Survived	1021 (92%)	1386 (92%)	2407 (92%)	
Died	91 (8%)	118 (8%)	209 (8%)	

Characteristics	Age continuous					Age dichotomous											
	Raw model		Adjusted model		Full model		Raw		Adjusted model		Full Model						
	OR (95% Cl) P		OR (95% CI) P		OR (95% CI) P		OR (95% CI)	Р	OR (95% CI)	Р	OR (95% CI)	Р					
Intervention (Y)	0.13 (0.02-1.10)	0.061	0.07 (0.01-0.79)	0.031	0.07 (0.01-0.80)	0.031	0.68 (0.02-1.10)	0.126	0.63 (0.36-1.06)	0.082	0.59 (0.34-1.03)	0.063					
Age	1.03 (1.01-1.05)	0.001	1.03 (1.01-1.05)	0.008	1.00 (0.99-1.03)	0.583	1.77 (1.14-2.77)	0.012	1.60 (1.00-2.59)	0.053	0.90 (0.54-1.51)	0.679					
Age * intervention	1.03 (1.00-1.05)	0.066	1.03 (1.00-1.06)	0.033	1.03 (1.00-1.07)	0.030	1.65 (0.90-3.05)	0.110	1.89 (0.99-3.63)	0.055	2.17 (1.11-4.30)	0.025					
Sex (F)					0.91 (0.66-1.24)	0.543					0.92 (0.67-1.26)	0.613					
Charlson comorbidity index (per point increase)			1.17 (1.09-1.25)	0.001	1.12 (1.04-1.20)	0.002			1.18 (1.10-1.26)	<0.001	1.12 (1.04-1.20)	0.003					
qSOFA (lower than 2)			0.46 (0.33-0.63)	0.001	0.56 (0.40-0.78)	<0.001			0.45 (0.33-0.62)	<0.001	0.55 (0.39-0.77)	<0.001					
Do not resuscitate order (Y)					3.75 (2.58-5.55)	<0.001					4.17 (2.88-6.14)	<0.001					
Antibiotics prior to hospital visit (Y)					1.34 (0.93-1.91)	0.111					1.32 (0.91-1.88)	0.132					
Immunosuppressive comedication (Y)					1.48 (1.00-2.16)	0.046					1.46 (0.98-2.13)	0.056					
Positive blood culture (Y)					1.37 (0.95-1.96)	0.088					1.38 (0.95-1.97)	0.084					
Ceftriaxone resistant pathogen (Y)				0	2.83 (0.38-14.00)	0.235					2.55 (0.33-13.35)	0.230					

Table 3. Associations of various traits with 28-day mortality through logistic regression modelling





Figure 2a. Visualization of clusters with k-means clustering based on age and heart rate (with temperature as the third clustering variable) segmented by intervention status and mortality outcome. 2b -. Mortality rate summary percentages with k-means clustering based on age, heart rate and temperature segmented by intervention status.

Randomization / 28-Day Mortality																									
Cluster	Survival								Fatal							Int	erv			Eat	tal				
cluster	89.61%					10 39%					90 58%							1			1 42	20%			
1	621								10	72 005								92							
	94.97% 359						7 Z							0		505 604			1.04			104			
2									5.03	5%0				9	5.9	0%0					4.04%				
								19							2	12T					19				
												Par	odomi	ization										Clust O 1	er
28-Day Mortality	•				Control				Kalldollii							Intervention									
	42						,	×	0								×	×		×			0	0	
	(snis	×	. ×	××××	× × ×	, ,*X)	× ******	n Š ie	806			0		×	××	× *****	*** ~~	×.,	×,			8 M		0	
	ss (Ce	*	⁽ xx)	*** × × ***~	*****	ě.							P b	×	×× ×××	<u>۲</u>			4) 0
Survival		×	~~~	~	×	*^*	××××	**************************************			004				*	××		~~~	×°	19975-1988 ×	008 0 ද)° °(jugo) o	
	ad 1 36-					×		×			ໍ່ຈ	D					× × ×				0	രള	60		
	₽ 34-			×		,	×	×		०	•									×	0	° °	0		
	54										Ŭ														
	42																								
	(snis							× (0	_		0								,	0	A a	90	0	
	e (Cel						×	×***	<u>}</u>			0						,	,,	×xXx	ຮິ				С
Fatal	-38- 38-				×		XX		000	968	во	8							×		é	0 a.es	000	0	
	Indu 36-					~			0	~										~ ×	0		0 8 0		
	₽ 24					^		c	o (50										^	0	0 0	° °		
	54																				0				
	20 30 40 50 60 70 80 90 100										0 20 30 40 50 60 70 80 90 100														
	Age (years)									Age (years)															